Catalent Inc (NASDAQ:CTLT) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.

CTLT has been the topic of several other research reports. Wells Fargo & Company reiterated an “outperform” rating and issued a $39.00 target price (up previously from $30.00) on shares of Catalent in a research report on Thursday, August 31st. J P Morgan Chase & Co reiterated a “buy” rating and issued a $40.00 target price on shares of Catalent in a research report on Tuesday, August 29th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Tuesday, August 22nd. William Blair reiterated an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $38.00 target price (up previously from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $36.22.

Shares of Catalent (CTLT) traded down 0.77% during mid-day trading on Friday, reaching $41.03. 493,308 shares of the company’s stock traded hands. The company’s 50 day moving average is $36.12 and its 200 day moving average is $33.05. Catalent has a 12-month low of $21.83 and a 12-month high of $42.22. The company has a market cap of $5.14 billion and a P/E ratio of 47.16.

Catalent (NASDAQ:CTLT) last announced its earnings results on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.08. Catalent had a net margin of 4.88% and a return on equity of 16.95%. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. During the same quarter last year, the business earned $0.52 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, analysts predict that Catalent will post $1.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/catalent-inc-ctlt-stock-rating-upgraded-by-bidaskclub.html.

In other news, SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

Several large investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Catalent in the second quarter worth about $538,000. Ameritas Investment Partners Inc. lifted its stake in shares of Catalent by 6.8% in the second quarter. Ameritas Investment Partners Inc. now owns 48,441 shares of the company’s stock worth $1,700,000 after buying an additional 3,064 shares in the last quarter. Nomura Holdings Inc. purchased a new position in shares of Catalent in the second quarter worth about $220,000. California State Teachers Retirement System lifted its stake in shares of Catalent by 13.6% in the second quarter. California State Teachers Retirement System now owns 222,934 shares of the company’s stock worth $7,825,000 after buying an additional 26,707 shares in the last quarter. Finally, 361 Capital LLC lifted its stake in shares of Catalent by 57.0% in the second quarter. 361 Capital LLC now owns 59,048 shares of the company’s stock worth $2,073,000 after buying an additional 21,437 shares in the last quarter.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.